{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:17:49Z","timestamp":1792811869224,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2023.100880","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T20:15:10Z","timestamp":1675887310000},"page":"100880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Drug\u2013drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-8953","authenticated-orcid":false,"given":"J.L.","family":"Raoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Moreau-Bachelard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gilabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Fr\u00e9nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.100880_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0091270009336137","article-title":"Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants","volume":"50","author":"Yin","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2023.100880_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmoop.2023.100880_bib4","doi-asserted-by":"crossref","first-page":"l1580","DOI":"10.1136\/bmj.l1580","article-title":"Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study","volume":"365","author":"Xie","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2023.100880_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13739","article-title":"Prevalence of proton pump inhibitor use among patients with cancer","volume":"4","author":"Raoul","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2023.100880_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2023.100880_bib7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/gutjnl-2017-315306","article-title":"Proton pump inhibitor use associated with changes in gut microbiota composition","volume":"67","author":"Reveles","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2023.100880_bib8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2023.100880_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"van Leeuwen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2023.100880_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ijc.31529","article-title":"Proton pump inhibitor use and cancer mortality","volume":"143","author":"Tvingsholm","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41416-021-01480-0","article-title":"Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study","volume":"125","author":"Wang","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bulcan.2019.12.009","article-title":"Proton pump inhibitors and cancers: a hazardous association?","volume":"107","author":"Raoul","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2036.1997.00182.x","article-title":"Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects","volume":"11","author":"Delchier","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canep.2016.12.006","article-title":"Proton pump inhibitors on pancreatic cancer risk and survival","volume":"46","author":"Kearns","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.esmoop.2023.100880_bib15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3390\/cancers14051156","article-title":"Long-term use of proton pump inhibitors in cancer patients: an opinion paper","volume":"14","author":"Raoul","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.100880_bib16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/bcp.15103","article-title":"Association of proton-pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials","volume":"88","author":"Veettil","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib17","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s10620-009-0951-9","article-title":"Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications","volume":"54","author":"Kedika","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.esmoop.2023.100880_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-015-0614-x","article-title":"Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis","volume":"13","author":"Ghebremariam","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.esmoop.2023.100880_bib19","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1023\/A:1026604203237","article-title":"Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells","volume":"44","author":"Ohara","year":"1999","journal-title":"Dig Dis Sci"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2023.100880_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2036.2000.014s1074.x","article-title":"A\u00a0new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions","volume":"14","author":"Yoshida","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.2008.00907.x","article-title":"A\u00a0succinct review of the general and immunological pharmacologic effects of proton pump inhibitors","volume":"33","author":"Namazi","year":"2008","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc.2017.77","article-title":"Tumour acidosis: from the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib24","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers12040998","article-title":"Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: a systematic review and meta-analysis","volume":"12","author":"Indini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.100880_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2023.100880_bib27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41467-019-14177-z","article-title":"Impact of commonly used drugs on the composition and metabolic function of the gut microbiota","volume":"11","author":"Vich Vila","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2023.100880_bib28","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","article-title":"Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes","volume":"71","author":"Ting","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2023.100880_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2023.100880_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2023.100880_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670286","article-title":"The potential role of the intestinal micromilieu and individual microbes in the immunobiology of chimeric antigen receptor T-cell therapy","volume":"12","author":"Schubert","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2023.100880_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2023.100880_bib33","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11096-019-00958-5","article-title":"Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis","volume":"42","author":"Wang","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.esmoop.2023.100880_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2022.02.007","article-title":"Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: the prospective IPPEM study","volume":"166","author":"Slimano","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.116.070722","article-title":"Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral human organic anion transporter 3","volume":"44","author":"Ikemura","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.esmoop.2023.100880_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","article-title":"Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial","volume":"3","author":"Chu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib39","first-page":"72","article-title":"Effects of proton pump inhibitors on FOLFOX and CapeOx regimens in colorectal cancer","volume":"18","author":"Wong","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib40","first-page":"257","article-title":"Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients","volume":"15","author":"Sun","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib41","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1038\/s41598-022-10008-2","article-title":"Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study","volume":"12","author":"Kitazume","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2023.100880_bib42","doi-asserted-by":"crossref","first-page":"e954","DOI":"10.1002\/onco.13735","article-title":"Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase III trial (AXEPT)","volume":"26","author":"Kim","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.100880_bib43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.6004\/jnccn.2020.7670","article-title":"Proton pump inhibitors and survival in patients with colorectal cancer receiving fluoropyrimidine-based chemotherapy","volume":"19","author":"Kichenadasse","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2023.100880_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cpt.2444","article-title":"Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial","volume":"111","author":"van Doorn","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib45","first-page":"375","article-title":"Performance of capecitabine in novel combination therapies in colorectal cancer","volume":"33","author":"Pouya","year":"2021","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.esmoop.2023.100880_bib46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaoncol.2016.3323","article-title":"Drug-drug interactions with oral antineoplastic agents","volume":"3","author":"Parsad","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/curroncol28010076","article-title":"Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists","volume":"28","author":"Uchiyama","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib48","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ctrv.2014.06.010","article-title":"Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions","volume":"40","author":"Peters","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2023.100880_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-020-00910-1","article-title":"Influence of cow\u2019s milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients","volume":"60","author":"Veerman","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2023.100880_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cllc.2014.07.005","article-title":"Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer","volume":"16","author":"Chu","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib51","doi-asserted-by":"crossref","first-page":"8539","DOI":"10.2147\/CMAR.S222278","article-title":"Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment \u2013 a nationwide population-based study","volume":"11","author":"Fang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2023.100880_bib52","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.31917","article-title":"The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clgc.2017.05.019","article-title":"Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"15","author":"Lalani","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib54","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1038\/s41598-022-10938-x","article-title":"Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2023.100880_bib55","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.2217\/fon-2020-0548","article-title":"Effect of comorbidities\/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry","volume":"16","author":"Boegemann","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib56","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib57","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib58","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jgo.2021.02.006","article-title":"VOTRAGE study: phase I dose-escalation study of pazopanib in unfit older patients","volume":"12","author":"Mourey","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib59","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.100880_bib60","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00228-020-02902-3","article-title":"Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma","volume":"76","author":"Van De Sijpe","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.2017-0578","article-title":"Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma","volume":"23","author":"McAlister","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.100880_bib62","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.3390\/cancers14194721","article-title":"Effect of concomitant proton pump inhibitors with pazopanib on cancer patients: a retrospective analysis","volume":"14","author":"Moreau-Bachelard","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.100880_bib63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/cpt.1331","article-title":"Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmacokinetic study","volume":"105","author":"de Man","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jcph.1035","article-title":"The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers","volume":"58","author":"Vishwanathan","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib65","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00228-022-03403-1","article-title":"Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study","volume":"78","author":"Yekeduz","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib66","article-title":"Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor","author":"Wu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2023.100880_bib67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MCG.0000000000001375","article-title":"Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma","volume":"55","author":"Razak","year":"2021","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.esmoop.2023.100880_bib68","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/hep.28737","article-title":"Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites","volume":"64","author":"Dam","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2023.100880_bib69","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00432-020-03261-3","article-title":"The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib","volume":"146","author":"Ruanglertboon","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.798272","article-title":"Proton pump inhibitors and cancer: current state of play","volume":"13","author":"Bridoux","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib71","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10637-020-01034-w","article-title":"Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers","volume":"39","author":"Li","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2023.100880_bib72","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.esmoop.2023.100880_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100231","article-title":"Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients","volume":"6","author":"Del Re","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.100880_bib74","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cpt.940","article-title":"Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations","volume":"104","author":"Samant","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.100880_bib75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12885-022-09624-y","article-title":"Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study","volume":"22","author":"Eser","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib76","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2023.100880_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929727","article-title":"Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer","volume":"10","author":"Qin","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2023.100880_bib78","article-title":"An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"suppl 10","key":"10.1016\/j.esmoop.2023.100880_bib80","doi-asserted-by":"crossref","first-page":"X40","DOI":"10.1093\/annonc\/mdy511.001","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","volume":"29","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib81","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/cancers14092300","article-title":"Proton pump inhibitor use and efficacy of nivolumab and ipilimumab in advanced melanoma","volume":"14","author":"Homicsko","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.100880_bib82","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib83","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2022.02.003","article-title":"Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials","volume":"17","author":"Hopkins","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib85","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ijc.33892","article-title":"Survival outcomes of patients with non-small cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors","volume":"150","author":"Baek","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib86","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2021.03.041","article-title":"Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy","volume":"150","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib87","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1111\/bcp.15276","article-title":"The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"88","author":"Wei","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2023.100880_bib88","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.100880_bib89","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.100880_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716317","article-title":"Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors","volume":"12","author":"Giordan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2023.100880_bib92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/10600280211033938","article-title":"Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients","volume":"56","author":"Peng","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmoop.2023.100880_bib93","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.21037\/atm-20-7498","article-title":"The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.esmoop.2023.100880_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11523-021-00861-y","article-title":"Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma","volume":"17","author":"Mollica","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib95","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.esmoop.2023.100880_bib96","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.100880_bib97","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s43018-021-00300-x","article-title":"Harnessing the microbiome to restore immunotherapy response","volume":"2","author":"Bullman","year":"2021","journal-title":"Nat Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:09Z","timestamp":1761856149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292300100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S205970292300100X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100880","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug\u2013drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100880"}}